In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Nijat Ahmadov, CEO of Nucs AI, about molecular imaging as one of pharma’s most underused data assets.
Nijat explains why PET, CT and other molecular imaging data remain largely “untouched”: clinically valuable and created at scale, but still too often trapped in qualitative reads rather than structured...